Because of the drug resistance and toxicity, the use of doxorubicin is limit in the clinic. This protocol provides a degradable carrier for keeping the release of this therapeutic agent. The advantage of this method is that the synthesized carrier
Melden Sie sich an oder starten Sie Ihre kostenlose Testversion, um auf diese Inhalt zuzugreifen
In this protocol, doxorubicin-loaded AS1411-g-PEI-g-PEG modified gold nanoparticles are synthesized via three-step amide reactions. Then, doxorubicin is loaded and delivered to target cancer cells for cancer therapy.